GLP-1 Makers Face Surge in Vision Loss Lawsuits Over Rare Eye Condition

Key points

• Over 100 lawsuits have been filed in New Jersey since 2025, with additional claims in Philadelphia, alleging that GLP-1 drugs like Ozempic and Zepbound caused NAION.
• NAION is a rare condition that causes sudden vision loss due to reduced blood flow to the optic nerve, typically affecting people over 50.
• The FDA is investigating the potential link, but no warning about NAION is currently on U.S. drug labels, unlike in the EU, UK, Australia, and Japan.
• Novo Nordisk and Eli Lilly deny a significant relationship between their drugs and NAION, noting that diabetic patients are already at higher risk for vision issues.
• Research on the link is mixed, with some studies showing an association and others finding no correlation, leading experts to conclude there is insufficient evidence for a definitive causal link.

Background

This story follows earlier reports from September 2026 detailing the initial surge in lawsuits and the debate over the NAION link. It also follows a March 2026 report on potential hair shedding side effects of GLP-1 drugs, highlighting ongoing scrutiny of the medication's safety profile.

How outlets are covering it

WCVB and USA Today emphasize the volume of lawsuits and the mixed research, while AZ Family highlights the personal impact on patients and the lack of U.S. warnings. Boston 25 News focuses on a specific patient's experience, illustrating the severity of the condition. All sources agree that the drugmakers deny causation and that the FDA is investigating.

Why it matters

The lawsuits and FDA investigation could lead to changes in drug labeling and prescribing practices, impacting millions of patients using GLP-1 drugs for weight loss and diabetes. The outcome will also influence the safety profile and public perception of these widely used medications.

What to watch

The FDA's investigation into the potential link between GLP-1 drugs and NAION is ongoing. The outcome of the lawsuits and the FDA's findings could lead to updated drug labels and warnings in the U.S., similar to those in other countries.